Witnesses at a House Energy and Commerce Health Subcommittee hearing urge lawmakers to modernize the nation's clinical trial system, and strengthen FDA’s scientific capacity to offset China’s rapidly growing share of early-stage drug development.
House Energy and Commerce Health Subcommittee leaders reveal differing views over whether the Trump administration's policies are strengthening or undermining the nation's drug development enterprise.
